Clinical Outcomes of Patients With Resectable Non-Small Cell Lung Cancer Receiving Neoadjuvant Nivolumab Plus Chemotherapy in France

Inclusion Criteria:

• Having a diagnosis of resectable non-small cell lung cancer (NSCLC)

• Being 18 years or above at the time of their NSCLC diagnosis

• Having initiated a neoadjuvant treatment with nivolumab and chemotherapy outside aclinical trial

• Being indexed in the site database

• Being followed at the site for at least 5 months, except for patients with a recordof death

Exclusion Criteria:

• Having any primary tumor other than NSCLC on or before the date of NSCLC diagnosis that required a treatment ending less than 12-months before the nivolumab plus chemotherapy neoadjuvant treatment